Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle-invasive Bladder Cancer × durvalumab × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 30 Carcinoma, Renal Cell 15 Prostatic Neoplasms 12 Carcinoma, Transitional Cell 10 Melanoma 8 Breast Neoplasms 7 Kidney Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Uterine Cervical Neoplasms 5 Triple Negative Breast Neoplasms 4 Small Cell Lung Carcinoma 4 Ovarian Neoplasms 4 Non-Muscle Invasive Bladder Neoplasms 4 Carcinoma, Merkel Cell 4 Squamous Cell Carcinoma of Head and Neck 3 Pancreatic Neoplasms 3 Head and Neck Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Hepatocellular 3 Urothelial Cancer 2 Testicular Neoplasms 2 Stomach Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Hodgkin Disease 2 Esophageal Neoplasms 2 Carcinoma in Situ 2 Carcinoma 2 Urinary Bladder Diseases 1 Turcot syndrome 1

Interventions

Drug Therapy 2 tremelimumab 1 pembrolizumab 1 enfortumab vedotin 1 durvalumab 1 atezolizumab 1 Watchful Waiting 1 Radiotherapy 1 Palliative Care 1 Magnetic Resonance Spectroscopy 1 Immunotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡